June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Clarin-1 expression in the inner retina: implications for gene therapy
Author Affiliations & Notes
  • Astra Dinculescu
    Ophthalmology, University of Florida, Gainesville, FL
  • Rachel M Stupay
    Ophthalmology, University of Florida, Gainesville, FL
  • Seok-Hong Min
    Ophthalmology, University of Florida, Gainesville, FL
  • Sanford L Boye
    Ophthalmology, University of Florida, Gainesville, FL
  • Vince Chiodo
    Ophthalmology, University of Florida, Gainesville, FL
  • William W Hauswirth
    Ophthalmology, University of Florida, Gainesville, FL
  • Footnotes
    Commercial Relationships Astra Dinculescu, None; Rachel Stupay, None; Seok-Hong Min, None; Sanford Boye, None; Vince Chiodo, None; William Hauswirth, AGTC (C), AGTC (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3632. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Astra Dinculescu, Rachel M Stupay, Seok-Hong Min, Sanford L Boye, Vince Chiodo, William W Hauswirth; Clarin-1 expression in the inner retina: implications for gene therapy. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3632.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Mutations in clarin-1 (CLRN1) gene are the cause of Usher syndrome type III (USH3A), an autosomal recessive disorder, manifested as retinitis pigmentosa (RP) and progressive hearing loss. One previous study showed that Clrn1 is expressed in mouse photoreceptor cells. Here, we show that Clrn1 protein expression can also be detected in the inner retina. In addition, we describe the use rAAV vectors for studies aimed at developing therapeutic strategies for the treatment of RP caused by USH3A mutations.

Methods: Adult C57BL/6 mouse retinal sections were immunostained with a commercially available antibody directed against clarin-1, and visualized by immunofluorescence microscopy. Gene replacement therapy using intravitreal delivery of AAV-vectors expressing the mouse Clrn1 protein under the control of the ubiquitous CBA promoter were performed in 1 Month old Clrn1 knockout (KO) and wild-type control mice. Retinal function was assessed periodically by electroretinography (ERG) starting at 2 months post-injection. Transgene expression in AAV-treated eyes was detected by RT-PCR and Western Blotting.

Results: Immunoreactivity for Clrn1 was detected in the inner retina, especially along the inner sublamina ending close to the ganglion cell layer in wild-type mice. The AAV-mediated gene-replacement strategy using an intravitreal approach resulted in a small, but significantly higher ERG amplitude in the Clrn1 KO group treated eyes relative to untreated partner eyes. Western blot analysis showed the presence of clarin protein tetramers similar to wild-type retinas in AAV-treated Clrn1 KO eyes but not in the contralateral controls.

Conclusions: Intravitreal delivery of clarin-1 using penetrating AAV vectors may represent a therapeutic strategy for the treatment of Ush3 retinal disorders, as it targets both the inner and outer retinal cells.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×